Log in

Relevant bibliographies by topics / Cancer Register / Journal articles

Journal articles on the topic 'Cancer Register'

To see the other types of publications on this topic, follow the link: Cancer Register.

Author: Grafiati

Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer Register.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Xie, Shao-Hua, Giola Santoni, Fredrik Mattsson, Eivind Ness-Jensen, and Jesper Lagergren. "Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)." BMJ Open 9, no. 1 (January 2019): e023155. http://dx.doi.org/10.1136/bmjopen-2018-023155.

Full text

Abstract:

PurposeThe Swedish Prescribed Drugs and Health Cohort (SPREDH) is a Swedish population-based cohort based on data from four nationwide health data registers, created with the aim of investigating how the use of selected medications influences cancer risk and other outcomes.ParticipantsThe cohort includes 8 421 115 users of selected common medications who have been followed-up for a total of 82 281 720 person-years from 1 July 2005 to 31 December 2015.Finding to dateThe data in SPREDH were prospectively collected from the following national health data registers in Sweden: Prescribed Drug Register, Patient Register, Cancer Register and Causes of Death Register. Data on basic patient characteristics, use of the selected common medications, healthcare utilisation, diagnoses (including detailed information on cancers), and dates and causes of death are available for all cohort participants. The cohort currently includes 801 766 incident cancer cases.Future plansThe data in SPREDH can be used for various types of epidemiological research, particularly for examining how the use of the selected medications influences disease risk and other outcomes. We are initially planning cohort studies and nested case-control studies on selected medications in relation to the risk and prognosis of oesophageal and gastric cancers.

APA, Harvard, Vancouver, ISO, and other styles

2

Häggström, Christel, Fredrik Liedberg, Oskar Hagberg, Firas Aljabery, Viveka Ströck, Abolfazl Hosseini, Truls Gårdmark, et al. "Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)." BMJ Open 7, no. 9 (September 2017): e016606. http://dx.doi.org/10.1136/bmjopen-2017-016606.

Full text

Abstract:

PurposeTo monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).ParticipantsThe SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.Findings to dateStudies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.Future plansThe SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.

APA, Harvard, Vancouver, ISO, and other styles

3

Bouhidel, Mohamed Larbi, Fayçal Beichi, Atika Bouhidel, Hachani Khadraoui, Imene Benamira, Mahdia Saidi, Abdelouahab Maaref, and Hocine Bounecer. "Cancer register in the Wilaya of Batna. The 2011 report." Batna Journal of Medical Sciences (BJMS) 2, no. 2 (December 30, 2012): 126–28. http://dx.doi.org/10.48087/bjmsoa.2015.2205.

Full text

Abstract:

Le registre du cancer de la wilaya de Batna est un registre de population, couvrant 1.173.852 habitants en 2011 (estimation avec un taux d’accroissement annuel de 1,58% à partir du recensement général de la population et de l’habitat RGPH 2008). Au total, 768 nouveaux cas de cancer ont été notifiés ; ce qui représente une incidence standardisée de 78,2 cas pour 100 000 habitants. Les cancers les plus fréquents chez l’homme sont respectivement : le cancer broncho-pulmonaire (12,2 cas/100 000 hbts) suivi du cancer colorectal et du cancer de la vessie. Chez la femme, le cancer du sein occupe largement le premier rang (25,2 cas/100 000 hbts) ce qui représente plus de 30% des cancers chez la femme. En deuxième position, se trouve le cancer colorectal suivi des cancers de la vésicule biliaire et de la thyroïde. La pathologie tumorale chez l’enfant (0-14 ans), dont l’incidence standardisée est de 1,9 cas/100 000 habitants, est dominée par le cancer du sang et des organes lymphoïdes.

APA, Harvard, Vancouver, ISO, and other styles

4

Stenbeck, Magnus. "Swedish cancer register: corrected data." Lancet 355, no. 9211 (April 2000): 1279. http://dx.doi.org/10.1016/s0140-6736(05)74713-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Fayers, Peter, Della Gibson, and Jean Mossman. "UKCCCR register of U.K. cancer trials." Controlled Clinical Trials 16, no. 3 (June 1995): 172–81. http://dx.doi.org/10.1016/0197-2456(94)00067-d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ganesan, S., D. Mehta, and L. Parvanta. "Cancer register documentation; are we accurate?" International Journal of Surgery 36 (November 2016): S52. http://dx.doi.org/10.1016/j.ijsu.2016.08.110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Fayers, Peter M., and Tim Armitage. "Towards an International Register of Cancer Trials: The UKCCCR register of U.K. trials." European Journal of Cancer 29, no. 6 (January 1993): 907–12. http://dx.doi.org/10.1016/s0959-8049(05)80436-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rohde, D., D. Rohde, K. Miller, and K. Miller. "Register Uro-Onkologischer Studien." Oncology Research and Treatment 26, no. 4 (2003): 35–42. http://dx.doi.org/10.1159/000074744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fayers, P. M. "The UKCCCR register of UK cancer trials." Clinical Oncology 7, no. 2 (January 1995): 72–76. http://dx.doi.org/10.1016/s0936-6555(05)80804-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Von Euler-Chelpin, My, Elsebeth Lynge, and Matejka Rebolj. "Register-based studies of cancer screening effects." Scandinavian Journal of Public Health 39, no. 7_suppl (July 2011): 158–64. http://dx.doi.org/10.1177/1403494811401479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Stattin, Pär, Fredrik Sandin, Karin Hellström, David Robinson, and Ingela Franck Lissbrant. "The National Prostate Cancer Register of Sweden." Tijdschrift voor Urologie 7, no. 2-3 (February 23, 2017): 50–59. http://dx.doi.org/10.1007/s13629-017-0168-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Nilsson, Martin, Björn Tavelin, and Bertil Axelsson. "A study of patients not registered in the Swedish cancer register but reported to the Swedish register of palliative care 2009 as deceased due to cancer." Acta Oncologica 53, no. 3 (August 22, 2013): 414–19. http://dx.doi.org/10.3109/0284186x.2013.819115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Alrkseeva, G. N., L. I. Gurina, L. F. Pisareva, M. V. Volkov, and N. V. Cherdyntseva. "Personalized approach to the treatment of metastatic kidney cancer." Pacific Medical Journal, no. 4 (December 28, 2020): 63–67. http://dx.doi.org/10.34215/1609-1175-2020-4-63-67.

Full text

Abstract:

Objective: Develop a new organizational form of a personalized approach to assign a target therapy to the patients with metastatic nephrocellular cancer concerning its clinical and economic effectiveness.Methods: The data by cancer register of the Primorsky region were used. 446 patients are included in the register, it allowed to estimate clinical-economic effectiveness of the target therapy by studying 88 cases.Results: 5 medicines were used: sunitrib, soraphenib, bevazizumab, everolimus and pazopanib. The control of the progress of the disease and the toxicity covered 44,3% of the patients. The toxicity of the 3–4th levels were registered during the treatment by inhibitors tyrozinkinaz. The target line therapy increased expenditures by 10% and allowed to increase overall survivability to 42 months.Conclusion: An electronic register of the patients provides monitoring, optimizes expenditures and increases the availability of the target therapy up to 19,7%. Sequential therapy is reasonable and provides the increase of the overall patients’ survivability.

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "CANCER AFTER TRANSPLANTATION: AGREEMENT OF REGISTRY RECORDS WITH STATE CANCER REGISTER." Transplantation 82, Suppl 2 (July 2006): 1006–7. http://dx.doi.org/10.1097/00007890-200607152-02857.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Erlikh, A. D., O. L. Barbarash, S. A. Berns, D. V. Duplyakov, A. A. Kondrashova, M. A. Cherkashin, and E. A. Shmidt. "Pulmonary embolism in cancer patients. SIRENA register data." Flebologiia 15, no. 3 (2021): 179. http://dx.doi.org/10.17116/flebo202115031179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ji, Jianguang, Jan Sundquist, and Kristina Sundquist. "Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study." European Respiratory Journal 48, no. 3 (May 12, 2016): 873–79. http://dx.doi.org/10.1183/13993003.00091-2016.

Full text

Abstract:

Familial clustering of pleural mesothelioma was reported previously, but none of the reports quantified the familial risk of mesothelioma or the association with other cancers. The contributions of shared environmental or genetic factors to the aggregation of mesothelioma were unknown.We used a number of Swedish registers, including the Swedish Multigeneration Register and the Swedish Cancer Register, to examine the familial risk of mesothelioma in offspring. Standardised incidence ratios (SIRs) were used to calculate the risk. Age standardised incidence rates of mesothelioma were calculated from the Swedish Cancer Registry.The incidence of mesothelioma reached its peak rate in 2000 and decreased thereafter. Risk of mesothelioma was significantly increased when parents or siblings were diagnosed with mesothelioma, with SIRs of 3.88 (95% CI 1.01–10.04) and 12.37 (95% CI 5.89–22.84), respectively. Mesothelioma was associated with kidney (SIR 2.13, 95% CI 1.16–3.59) and bladder cancers (SIR 2.09, 95% CI 1.32–3.14) in siblings. No association was found between spouses.Family history of mesothelioma, including both parental and sibling history, is an important risk factor for mesothelioma. Shared genetic factors may contribute to the observed familial clustering of mesothelioma, but the contribution of shared environmental factors could not be neglected. The association with kidney and bladder cancers calls for further study to explore the underlying mechanisms.

APA, Harvard, Vancouver, ISO, and other styles

17

Horne, AnnaCarin, Bénédicte Delcoigne, Karin Palmblad, and Johan Askling. "Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies." RMD Open 5, no. 2 (November 2019): e001055. http://dx.doi.org/10.1136/rmdopen-2019-001055.

Full text

Abstract:

BackgroundThe risk of cancer, including any secular trends in risk, in patients with juvenile idiopathic arthritis (JIA) is incompletely understood.MethodsWe performed a register-based cohort study of patients with JIA from 2001 until 2017, identified via the Swedish Patient Register. Patients with JIA were matched to five population reference subjects. Patients and referents were followed up for incident cancers (via linkage to the Swedish Cancer Register) until 18 years of age or 31 December 2016.ResultsAmong the 6721 patients with JIA, we observed 10 incident malignancies (5 lymphoproliferative cancers) during 34 951 person-years of follow-up, corresponding to an excess incidence of 0.09 cancers per 1000 person-years (one extra case per 11 000 patients per year), an HR for cancer (all sites) of 1.4 (95% CI 0.7 to 2.9) and an HR for lymphoproliferative malignancies of 3.6 (95% CI 1.1 to 11.2). The rates of cancer in JIA did not increase over the study period. We noted no differences in the excess risk comparing periods before and after the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs).DiscussionChildren and adolescents with JIA are at a slightly increased risk of lymphoproliferative (but not of other) malignancies. At the group level, there is no sign that this risk has increased further after the introduction of bDMARDs.

APA, Harvard, Vancouver, ISO, and other styles

18

Kampitsi, Christina-Evmorfia, Hanna Mogensen, Maria Feychting, and Giorgio Tettamanti. "The relationship between congenital heart disease and cancer in Swedish children: A population-based cohort study." PLOS Medicine 19, no. 2 (February 25, 2022): e1003903. http://dx.doi.org/10.1371/journal.pmed.1003903.

Full text

Abstract:

Background Birth defects have been consistently associated with elevated childhood cancer risks; however, the relationship between congenital heart disease (CHD) and childhood cancer remains conflicting. Considering the increasing patient population with CHD after improvements in their life expectancies, insights into this relationship are particularly compelling. Thus, we aimed to determine the relationship between CHD and cancer in Swedish children. Methods and findings All individuals registered in the Swedish Medical Birth Register (MBR) between 1973 and 2014 were included in this population–based cohort study (n = 4,178,722). Individuals with CHD (n = 66,892) were identified from the MBR and National Patient Register, whereas cancer diagnoses were retrieved from the Swedish Cancer Register. The relationship between CHD and childhood cancer (<20 years at diagnosis) was evaluated using Cox proportional hazards regression models. We observed increased risks of cancer overall, leukemia, lymphoma, and hepatoblastoma in children with CHD, but after adjustment for Down syndrome, only the increased lymphoma (hazard ratio (HR) = 1.64, 95% confidence interval (CI) 1.11 to 2.44) and hepatoblastoma (HR = 3.94, 95% CI 1.83 to 8.47) risk remained. However, when restricting to CHD diagnoses from the MBR only, i.e., those diagnosed around birth, the risk for childhood cancer overall (HR = 1.45, 95% CI 1.23 to 1.71) and leukemia (HR = 1.41, 95% CI 1.08 to 1.84) was more pronounced, even after controlling for Down syndrome. Finally, a substantially elevated lymphoma risk (HR = 8.13, 95% CI 4.06 to 16.30) was observed in children with complex CHD. Limitations of the study include the National Patient Register not being nationwide until 1987, in addition to the rareness of the conditions under study providing limited power for analyses on the rarer cancer subtypes. Conclusions We found associations between CHD and childhood lymphomas and hepatoblastomas not explained by a diagnosis of Down syndrome. Stronger associations were observed in complex CHD.

APA, Harvard, Vancouver, ISO, and other styles

19

Ruco, Arlinda, Fahima Dossa, Jill Tinmouth, Diego Llovet, Jenna Jacobson, Teruko Kishibe, and Nancy Baxter. "Social Media and mHealth Technology for Cancer Screening: Systematic Review and Meta-analysis." Journal of Medical Internet Research 23, no. 7 (July 30, 2021): e26759. http://dx.doi.org/10.2196/26759.

Full text

Abstract:

Background Cancer is a leading cause of death, and although screening can reduce cancer morbidity and mortality, participation in screening remains suboptimal. Objective This systematic review and meta-analysis aims to evaluate the effectiveness of social media and mobile health (mHealth) interventions for cancer screening. Methods We searched for randomized controlled trials and quasi-experimental studies of social media and mHealth interventions promoting cancer screening (breast, cervical, colorectal, lung, and prostate cancers) in adults in MEDLINE, Embase, PsycINFO, Scopus, CINAHL, Cochrane Central Register of Controlled Trials, and Communication & Mass Media Complete from January 1, 2000, to July 17, 2020. Two independent reviewers screened the titles, abstracts, and full-text articles and completed the risk of bias assessments. We pooled odds ratios for screening participation using the Mantel-Haenszel method in a random-effects model. Results We screened 18,008 records identifying 39 studies (35 mHealth and 4 social media). The types of interventions included peer support (n=1), education or awareness (n=6), reminders (n=13), or mixed (n=19). The overall pooled odds ratio was 1.49 (95% CI 1.31-1.70), with similar effect sizes across cancer types. Conclusions Screening programs should consider mHealth interventions because of their promising role in promoting cancer screening participation. Given the limited number of studies identified, further research is needed for social media interventions. Trial Registration PROSPERO International Prospective Register of Systematic Reviews CRD42019139615; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=139615 International Registered Report Identifier (IRRID) RR2-10.1136/bmjopen-2019-035411

APA, Harvard, Vancouver, ISO, and other styles

20

Askling, Johan. "From bedside to register, and back again - How can epidemiological studies using register-data influence clinical practice?" European Journal of Cancer 37 (April 2001): S246. http://dx.doi.org/10.1016/s0959-8049(01)81399-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hammerlid, Eva B., Erik Holmberg, Anders Högmo, Göran Laurell, Magnus Niklasson, Johan Wennerberg, and Anders Westerborn. "Results from the Swedish Head and Neck Cancer Register for Oral Cancer." Otolaryngology–Head and Neck Surgery 147, no. 2_suppl (August 2012): P176. http://dx.doi.org/10.1177/0194599812451426a162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Sylvest, R., D. Vassard, L. Schmidt, K. Schmiegelow, K. T. Macklon, J. L. Forman, and A. Pinborg. "Parenthood among men diagnosed with cancer in childhood and early adulthood: trends over time in a Danish national cohort." Human Reproduction 36, no. 9 (June 24, 2021): 2576–86. http://dx.doi.org/10.1093/humrep/deab154.

Full text

Abstract:

Abstract STUDY QUESTION Is the rate of fatherhood among men diagnosed with cancer in childhood and early adulthood different from men without cancer, and, if so, have the differences changed over time? SUMMARY ANSWER Men diagnosed with cancer have had significantly reduced rates of fatherhood compared with undiagnosed men; however, the rates of fatherhood among the cancer survivors have increased markedly over time. WHAT IS KNOWN ALREADY The number of children and young adolescents who survive cancer has steadily increased over recent decades, with a current 5-year survival rate of approximately 80%. Consequently, life circumstances after cancer have gained increasing importance, including the desire among survivors to have children and a family. ARTs to aid reproduction among cancer survivors have been developed, and fertility preservation is increasingly a topic being discussed before undergoing cancer treatment. But the potential for fertility preservation differs dependent on age at diagnosis and type of cancer. Earlier studies have shown a decreased fertility rate among survivors of child and adolescent cancer compared to those diagnosed in early adulthood. STUDY DESIGN, SIZE, DURATION This study is a national, register-based cohort study. Men diagnosed with cancer in childhood and early adulthood (<30 years of age) were registered in the Danish Cancer Register in 1978–2016 (n = 9353). According to the time of diagnosis, each cancer-diagnosed man was randomly matched with 150 undiagnosed men from the background population within the same birth year. The men were followed until having their first child, death, migration or the end of the study (31 December 2017) in medical registers and socio-demographic population registers. PARTICIPANTS/MATERIALS, SETTING, METHODS Fatherhood among the boys and young men diagnosed with cancer were compared with the age-matched comparison group in all statistical analyses. Cancer diagnoses were categorised as central nervous system (CNS) cancers, haematological cancers or solid cancers. Analyses were stratified by age at diagnosis (0–9, 10–19, 20–29 years) and time of diagnosis (1978–1989, 1990–1999, 2000–2009, 2010–2016). Death was incorporated as a competing risk in all analyses. MAIN RESULTS AND THE ROLE OF CHANCE The study population consisted of 9353 boys and young men diagnosed with cancer between 1978 and 2016 and 1 386 493 men in the age-matched comparison group. Those surviving CNS cancer as young men had the lowest hazard ratio (HR) of fatherhood compared with the age-matched comparison group (HR 0.67, 95% CI 0.57–0.79), followed by survivors of haematological cancers (HR 0.90, 95% CI 0.81–1.01), while the highest chance of fatherhood was among survivors of solid cancers (HR 1.16, 95% CI 1.12–1.20) with a slightly increased HR compared with undiagnosed males. The HR of becoming a father increased over time. From the first decade to the last decade 30 years later, the HR of becoming a father increased for solid tumours (HR 0.78, 95% CI 0.73–0.83 to HR 1.08, 95% CI 0.95–1.22), haematological cancers (HR 0.64, 95% CI 0.53–0.79 to HR 0.97, 95% CI 0.73–1.30) and CNS cancers (HR 0.44, 95% CI 0.34–0.57 to HR 0.98, 95% CI 0.49–1.95) compared to the age-matched comparison group. Also, when compared with the age-matched comparison group, men diagnosed with cancer when aged 20–29 years were more likely became fathers over the time of the study (HR 0.80, 95% CI 0.74–0.86 to HR 1.08, 95% CI 0.96–1.22). LIMITATIONS, REASONS FOR CAUTION The study was based on register data, and information was not available about the men’s fertility potential, whether they had a desire to have children and whether it was possible for them to find a partner. Information about fertility preservation, e.g. sperm freezing, could also have provided additional insights. Furthermore, information about diagnosis and ART treatment would have been beneficial. WIDER IMPLICATIONS OF THE FINDINGS Information and education of male patients diagnosed with cancer about fertility preservation options and their chances to create their own family is crucial. Reassuringly, time trends showed more men with a previous cancer diagnosis becoming fathers in recent years than in earlier years, reflecting that survival and fertility preservation have improved over time. STUDY FUNDING/COMPETING INTEREST(S) R.S. received a PhD grant from the Rosa Ebba Hansen Foundation and from the Health Foundation (J.nr. 15-B-0095). The funding for the establishment of the DANAC II Cohort was obtained from the Rosa Ebba Hansen Foundation. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER N/A.

APA, Harvard, Vancouver, ISO, and other styles

23

Seppälä, Laura K., Laura-Maria Madanat-Harjuoja, Maarit K. Leinonen, Mitja Lääperi, and Kim Vettenranta. "Maternal Thyroid Disease and the Risk of Childhood Cancer in the Offspring." Cancers 13, no. 21 (October 28, 2021): 5409. http://dx.doi.org/10.3390/cancers13215409.

Full text

Abstract:

Maternal thyroid disease, especially hypothyroidism, affects pregnancy and its outcome. In-utero exposure to autoimmune thyroid disease has been reported to associate with childhood ALL in the offspring. We evaluated the risk of childhood cancer in the offspring following exposure to maternal thyroid disease in a case-control setting using registry data. All patients with their first cancer diagnosis below the age of 20 years were identified from the Finnish Cancer Registry (n = 2037) and matched for sex and birth year at a 1:5 ratio to population controls identified from the Medical Birth Registry (n = 10,185). We collected national information on maternal thyroid disease from the Medical Birth Registry, Care Register for Health Care, Register for Reimbursed Drug Purchases and Register of Special Reimbursements. We used conditional logistic regression to analyze childhood cancer risk in the offspring. The adjusted OR for any childhood cancer was 1.41 (95%, CI 1.00–2.00) comparing the offspring of mothers with hypothyroidism and those with normal thyroid function. The risk of lymphomas was increased (adjusted OR for maternal hypothyroidism 3.66, 95%, CI 1.29–10.38). The results remained stable when mothers with cancer history were excluded from the analyses. Maternal hypothyroidism appears to be associated with an increased risk for childhood lymphoma in the offspring. The association exists even after excluding possible familial cancers.

APA, Harvard, Vancouver, ISO, and other styles

24

WILBRAND, S., A. EKBOM, and B. GERDIN. "Cancer Incidence in Patients Treated Surgically for Dupuytren’s Contracture." Journal of Hand Surgery 25, no. 3 (June 2000): 283–87. http://dx.doi.org/10.1054/jhsb.2000.0382.

Full text

Abstract:

Our aim was to study risk factors for Dupuytren’s contracture (DC) by assessing cancer morbidity in a group of Swedish patients treated surgically for Dupuytren’s contracture. The risk of cancer was determined in 15,212 patients operated on for Dupuytren’s contracture, identified in the nation-wide Swedish Inpatient Register during the period 1965 to 1994 by means of record linkage to the Swedish Cancer Register. Standardized incidence ratios (SIRs) were computed using age-, sex- and period-specific incidence rates derived from the entire Swedish population. The overall relative risk of cancer was increased by 24%. There were significantly increased risks for malignancies related to smoking such as buccal, oesophageal, gastric, lung and pancreatic cancers. Significantly increased risks were present for both prostate and rectal cancer in men and an increase risk for breast cancer in women was noted 1 year or more after surgery for Dupuytren’s contracture. The present study confirms smoking and alcohol abuse as probable risk factors for DC. There are characteristics in patients with DC that alter the risks for other malignancies compared with the general population.

APA, Harvard, Vancouver, ISO, and other styles

25

Minakov, S. N., Yu V. Levina, and M. Y. Prostov. "Population based cancer register. Functionality, challenges, and existing problems." Malignant tumours 9, no. 1 (April 10, 2019): 6–9. http://dx.doi.org/10.18027/2224-5057-2019-9-1-6-9.

Full text

Abstract:

Introduction of possibilities ways of using modern information technologies in the organizational and therapeutic activities of medical organizations of the health care system of the Russian Federation(Russia) is one of the most important tools in implementation of the state policy of providing quality medical care to the population. Information systems (IS) allow to monitor and record data on patients with malignant neoplasms, to reflect diagnosis data, treatment, to present various thematic analytical reports, which increases the data analysis efficiency, diagnostic methods effectiveness, which, in turn, provides possibilities for high‑quality treatment of patients with malignant neoplasms and timely monitoring of their condition.

APA, Harvard, Vancouver, ISO, and other styles

26

Green, J., F. Murton, and H. Statham. "Psychosocial issues raised by a familial ovarian cancer register." Journal of Medical Genetics 30, no. 7 (July 1, 1993): 575–79. http://dx.doi.org/10.1136/jmg.30.7.575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Terveschenko, I. V., and E. M. Slonlmskaya. "Formation of the regional register of hereditary breast cancer." European Journal of Cancer 33 (September 1997): S131. http://dx.doi.org/10.1016/s0959-8049(97)85132-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Wirdefeldt, K., C. E. Weibull, H. Chen, F. Kamel, C. Lundholm, F. Fang, and W. Ye. "Parkinson's Disease and Cancer: A Register-based Family Study." American Journal of Epidemiology 179, no. 1 (October 18, 2013): 85–94. http://dx.doi.org/10.1093/aje/kwt232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Persson, Beata, Jan-Gunnar Sjödin, Lars Holmberg, Torgny Windahl, Beata Persson, Jan-Gunnar Sjödin, Lars Holmberg, and Torgny Windahl. "The National Penile Cancer Register in Sweden 2000–2003." Scandinavian Journal of Urology and Nephrology 41, no. 4 (January 2007): 278–82. http://dx.doi.org/10.1080/00365590601183709.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hansson, Markus, Niels Abildgaard, Anders Waage, Pekka Anttila, Anders Green, Katrine Hass Rubin, Lill-Brith von Arx, et al. "Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study." Blood 134, Supplement_1 (November 13, 2019): 5037. http://dx.doi.org/10.1182/blood-2019-121983.

Full text

Abstract:

Introduction Multiple myeloma (MM) is an incurable but treatment sensitive plasma cell cancer with an average survival of 2-5 years following diagnosis, depending on age and stage. Few studies report real-world data in MM, with limited estimations of incidence and prevalence. The Health Outcome and Understanding of Myeloma - a multi-national real-world evidence (HUMANS) study utilized real-world data from nationwide registers in Sweden and Denmark, with almost complete population coverage, to estimate the incidence and prevalence of MM. Methods This population-based, retrospective, observational, cohort study used linked, secondary data from national healthcare registers in Sweden (National Patient Register [NPR], Cancer Register [CR], Cause of Death [COD], and Prescription Drug Register [PDR]) and Denmark (NPR and CR) from 2005-2018. Patients with MM diagnosis recorded in the NPR and/or CR treated and untreated with MM specific drugs were included. The NPR in both countries is a hospital discharge register, in which patients receive an ICD-10 diagnosis each time they visit outpatient or inpatient care as the main reason for the hospital visit. The CR is manually reported by physicians when a cancer diagnosis is confirmed. In Denmark, the CR is automatically connected to the NPR, thereby obliging physicians to register whether a diagnosis is confirmed upon first NPR ICD-10 code registration of a cancer diagnosis. The Swedish CR requires active registration of a pathologist or treating hematologist to confirm the diagnosis. To determine the completeness of registration in each respective CR, treatments from the Swedish PDR and Danish NPR from 2010-2018 were used to assess incident NPR cases. Treated patients registered in the NPR, but not in the CR (NPR+/CR-) were compared with treated patients registered in both (NPR+/CR+) to assess any systematic reasons for lack of CR registration. Final inclusion criteria were determined for best estimate of incidence/prevalence of MM. Prevalence was defined as the number of non-deceased patients with MM recorded during each calendar year, as assessed from the COD register. Incidence and prevalence rates were calculated as the crude incident and prevalent cases, divided by the patients at risk (total population minus prevalent population) for each year and multiplied by 100,000. Results In Sweden, data for 13,523 unique patients with registered MM was collected. Of these, 4,563 and 874 fulfilled the inclusion criteria of NPR+/CR+ and NPR+/CR-, respectively. In the comparative analysis, NPR+/CR+ and NPR+/CR- patients had a similar frequency of treatment at a hematology department (57% of NPR+/CR+ and 53% of NPR+/CR- patients had ≥1 visit ), and had a similar share of patients with autologous stem cell transplant (22% for NPR+/CR+ and 18% for NPR+/CR-), and of MM pharmacological treatment type (53% for NPR+/CR+ and 47% for NPR+/CR- had ≥1 prescription of lenalidomide). Both university hospitals and general hospitals had a high share of NPR+/CR- patients. As no systematic difference was found for patients registered in the CR or not, we considered the estimate of incidence to be a sum of NPR+/CR+ treated AND untreated + NPR+/CR- treated. In Denmark, data for 6331 unique patients with registered MM were collected. Of these, 3,680 met inclusion criteria for NPR+/CR+ and 233 for NPR+/CR-. Patients registered as NPR+/CR- were 33% more commonly not visiting a hematology department versus NPR+/CR+. Thus, a systematic skew in CR misregistration could not be excluded. We propose the best estimate of incidence and prevalence of MM in Denmark to be patients registered in the NPR and CR (treated or untreated). In Sweden and Denmark, incidence and prevalence were higher in patients aged ≥70 versus <70 years, and in males versus females. Between the two countries, incidence and prevalence of MM were generally similar, with slightly higher prevalence in Sweden (vs Denmark) and incidence in Denmark (vs Sweden) in patients aged ≥ 70 years (Tables 1 and 2). Best estimates for validated incidences of MM were largely similar to those reported in the Swedish and Danish myeloma registries (Table 3). Conclusion The use of several nationwide registries with independent case registration, rigorous inclusion criteria, and careful consideration of criteria used to estimate incidence/prevalence, arguably provides improved estimates of incidence/prevalence compared with previous studies. Disclosures Abildgaard: Takeda: Research Funding; Celgene: Research Funding; Amgen: Research Funding; Janssen: Research Funding. Szilcz:Parexel International: Employment. Ma:Parexel International: Employment. Ørstavik:Takeda Pharmaceuticals International AG: Employment. Bent-Ennakhil:Takeda Pharmaceuticals International AG: Employment. Freilich:Parexel International: Employment. Gavini:Takeda Pharmaceuticals International AG: Employment.

APA, Harvard, Vancouver, ISO, and other styles

31

Sandblom, Gabriel, Monika Dufmats, Mats Olsson, and Eberhard Varenhorst. "Validity of a Population-Based Cancer Register in Sweden An Assessment of Data Reproducibility in the South-East Region Prostate Cancer Register." Scandinavian Journal of Urology and Nephrology 37, no. 2 (January 2003): 112–19. http://dx.doi.org/10.1080/00365590310008839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tettamanti, Giorgio, Rickard Ljung, Anders Ahlbom, Mats Talbäck, Birgitta Lannering, Tiit Mathiesen, Jenny Pettersson Segerlind, and Maria Feychting. "Central nervous system tumor registration in the Swedish Cancer Register and Inpatient Register between 1990 and 2014." Clinical Epidemiology Volume 11 (January 2019): 81–92. http://dx.doi.org/10.2147/clep.s177683.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Beckmann, Kerri, Hans Garmo, Ingela Franck Lissbrant, and Pär Stattin. "The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries." Cancers 13, no. 4 (February 19, 2021): 875. http://dx.doi.org/10.3390/cancers13040875.

Full text

Abstract:

Real-world data (RWD), that is, data from sources other than controlled clinical trials, play an increasingly important role in medical research. The development of quality clinical registers, increasing access to administrative data sources, growing computing power and data linkage capacities have contributed to greater availability of RWD. Evidence derived from RWD increases our understanding of prostate cancer (PCa) aetiology, natural history and effective management. While randomised controlled trials offer the best level of evidence for establishing the efficacy of medical interventions and making causal inferences, studies using RWD offer complementary evidence about the effectiveness, long-term outcomes and safety of interventions in real-world settings. RWD provide the only means of addressing questions about risk factors and exposures that cannot be “controlled”, or when assessing rare outcomes. This review provides examples of the value of RWD for generating evidence about PCa, focusing on studies using data from a quality clinical register, namely the National Prostate Cancer Register (NPCR) Sweden, with longitudinal data on advanced PCa in Patient-overview Prostate Cancer (PPC) and data linkages to other sources in Prostate Cancer data Base Sweden (PCBaSe).

APA, Harvard, Vancouver, ISO, and other styles

34

Rimaitis, K., and D. Pavalkis. "Does epidural anesthesia and analgesia really improves surgical outcome after colorectal cancer surgery." Acta chirurgica Iugoslavica 53, no. 2 (2006): 85–89. http://dx.doi.org/10.2298/aci0602085r.

Full text

Abstract:

Lithuanian Cancer Register has registered 1443 new cases of colorectal cancer in 2004 and this value constantly increases about 200 cases per year 1. Colorectal cancer is on the third place among all cancer patients in our country. Colorectal cancer surgery is associated with a major surgical trauma. Majority of recent randomized clinical trials (RCT) has shown that combined general - epidural anesthesia and postoperative epidural analgesia has demonstrated some beneficial effects and improved surgical outcome in various fields of surgery 2-4. However controversies still exist about epidural anesthesia and analgesia effects on colorectal anastomosis and it?s influence on patients? outcome.

APA, Harvard, Vancouver, ISO, and other styles

35

Momen, Natalie C., Linn Håkonsen Arendt, Andreas Ernst, Jørn Olsen, Jiong Li, Mika Gissler, and Cecilia H. Ramlau-Hansen. "Pregnancy-associated cancers and birth outcomes in children: a Danish and Swedish population-based register study." BMJ Open 8, no. 12 (December 2018): e022946. http://dx.doi.org/10.1136/bmjopen-2018-022946.

Full text

Abstract:

ObjectivesThis study aims to estimate the association between pregnancy-associated maternal cancers, diagnosed both prenatally and postnatally, and birth outcomes.DesignPopulation-based register study.SettingNational registers of Denmark and Sweden.ParticipantsA total of 5 523 365 children born in Denmark (1977–2008) and Sweden (1973–2006).Primary and secondary outcome measures: gestational age, birth weight, size for gestational age, Apgar score, caesarean section and sex were the outcomes of interest. ORs and relative risk ratios (RRR) with 95% CIs were estimated using logistic regression and multinomial logistic regression, respectively.ResultsIn this study, 2% of children were born to mothers with a diagnosis of cancer. Children whose mothers received a prenatal cancer diagnosis had higher risk of being born preterm (RRR: 1.77, 95% CI 1.64 to 1.90); low birth weight (RRR 1.84, 95% CI 1.69 to 2.01); low Apgar score (OR 1.36, 95% CI 1.20 to 1.56); and by caesarean section (OR: 1.69, 95% CI 1.59 to 1.80). Associations moved towards the null for analyses using postnatal diagnoses, but preterm birth (RRR: 1.13, 95% CI 1.09 to 1.17) and low birth weight (RRR: 1.14, 95% CI 1.09 to 1.18) remained statistically significant, while risk of caesarean section became so (OR: 0.95, 95% CI 0.91 to 0.98). Additionally, statistical significance was reached for large for gestational age (RRR: 1.06, 95% CI 1.01 to 1.11), high birth weight (RRR: 1.04, 95% CI 1.01 to 1.06) and caesarean section (OR: 0.95, 95% CI 0.91 to 0.98).ConclusionsResults suggest an association between pregnancy-associated cancers and adverse birth outcomes in the offspring. While this is strongest for prenatally diagnosed cancers, some smaller associations exist for postnatally diagnosed cancers, indicating that cancer itself could affect fetal development, or that cancer and adverse birth outcomes share risk factors. Future studies on maternal cancer during pregnancy should consider including some postnatal years in their exposure window.

APA, Harvard, Vancouver, ISO, and other styles

36

Miao Jonasson, Junmei, Jan Cederholm, and Soffia Gudbjornsdottir. "Excess Body Weight and Cancer Risk in Patients with Type 2 Diabetes Who Were Registered in Swedish National Diabetes Register – Register-Based Cohort Study in Sweden." PLoS ONE 9, no. 9 (September 8, 2014): e105868. http://dx.doi.org/10.1371/journal.pone.0105868.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Hultcrantz, Malin, Therese M.-L. Andersson, Ola Landgren, Paul W. Dickman, Bjorn Andreasson, Magnus Bjorkholm, and Sigurdur Y. Kristinsson. "A Population-Based Study of Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012." Blood 126, no. 23 (December 3, 2015): 1605. http://dx.doi.org/10.1182/blood.v126.23.1605.1605.

Full text

Abstract:

Abstract Background The Myeloproliferative neoplasms (MPNs) consists of the subtypes polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and MPN unclassifiable (MPN-U). The incidence rates of these diseases vary substantially between different reports, ranging from 1.15 to 4.99/100,000 person-years. However, in a recent metaanalysis, there was no significant difference in MPN incidence between Europe and North America and the variations in incidence may therefore reflect the quality of the cancer registers and reporting of MPNs. In addition, there is a limited number of reports on MPN incidence during more recent years. Therefore, we assessed the incidence of MPN based on the Swedish Cancer Register, a high-quality population-based cancer register between 2000 and 2012. Patients and Methods The Swedish Cancer Register was used to identify all patients diagnosed with an MPN between January 1st 2000 and December 31st 2012. These Swedish Cancer Registers have very high levels of quality and completeness. Between 2008 and 2012, the reporting of newly diagnosed MPN to the cancer register was >92%. Information on the Swedish population was obtained from the Human Mortality Database (www.mortality.org). Based on information from these registers, incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Confidence intervals were estimated on the log scale. In addition, the incidence rate in relation to MPN subtype, age group (18-39, 40-49, 50-59, 60-69, 70-79, and ³80 years), as well as calendar year of diagnosis was assessed. Results A total of 5,442 MPN patients were reported to the cancer register between 2000 and 2012. During these years, there were 1,810 incident cases of PV, 1,862 of ET, 636 of PMF, and 1,134 with MPN-U. Between January 1st 2000 and December 31st 2012, the population in Sweden increased from 8,861,426 to 9,555,893 inhabitants. The overall annual incidence rate of MPN was 5.83 (95% CI 5.68-5.99)/100,000 persons. The incidence rate of PV was 1.94 (1.85-2.03), ET 2.00 (1.91-2.09), PMF 0.68 (0.63-0.74), and MPN-U 1.22 (1.15-1.29) per 100,000 person-years. In addition, there was a strong correlation between age and incidence of MPN with incidence rates being substantially higher among the older age groups (Table). The overall incidence rate of MPNs increased during the study period, from 5.06 (4.55-5.62)/100,000 person-years in the year 2000 to 5.98 (5.45-6.55)/100,000 person-years in 2012. The incidence rate of PV was similar throughout the study period, the incidence was 2.05 (1.74-2.42)/100,000 person-years in 2000 and 2.12 (1.81-2.47)/100,000 person-years in 2012. The annual incidence rate of ET and PMF increased, from 1.62 (1.34-1.95) to 2.49 (2.15-2.87) per 100,000 persons for ET and from 0.36 (0.24-0.53) to 0.86 (0.67-1.10) per 100,000 persons for PMF between 2000 and 2012. Conversely, the incidence of MPN-U decreased, 1.03 (0.81-1.29) to 0.52 (0.38-0.71)/100,000 person-years between 2000 and 2012. Summary and Conclusions In this large population-based study, the incidence of MPN was higher than previously reported in both European and North American studies. As earlier lower incidence rates likely are an effect of limited coverage of cancer registers, there may be an underreporting of MPNs in many European and American countries. The increase in MPN incidence rates during the study period may reflect increasing life expectancy of the Swedish population, improved reporting to the cancer register as well as changes in the classification and diagnostic systems. Similarly, the decrease in incidence of MPN-U is also likely a result of improved diagnostics during more recent years. In conclusion, the MPN incidences rates reported here are presumably more accurate compared to earlier reports due to the high level of coverage and accuracy of the Swedish registers. Table 1. Incidence rates of MPNs overall and in relation to subtype and age at diagnosis Total number MPN diagnosed 2000-2012 Incidence/100 000 person-years (95% confidence interval) All MPN 5,442 5.83 (5.68-5.99) Subtype PV 1,810 1.94 (1.85-2.03) ET 1,862 2.00 (1.91-2.09) PMF 636 0.68 (0.63-0.74) MPN-U 1,134 1.22 (1.15-1.29) Age at diagnosis (years) 18-39 226 0.67 (0.59-0.76) 40-49 361 2.26 (2.04-2.51) 50-59 769 4.92 (4.58-5.28) 60-69 1,228 9.54 (9.02-10.1) 70-79 1,680 18.99 (18.1-19.9) >80 1,178 18.92 (17.87-20.03) Disclosures Landgren: BMJ Publishing: Honoraria; Bristol-Myers Squibb: Honoraria; Medscape: Honoraria; Onyx: Honoraria; Celgene: Honoraria; International Myeloma Foundation: Research Funding; Medscape: Consultancy; BMJ Publishing: Consultancy; Onyx: Research Funding; Bristol-Myers Squibb: Consultancy; Onyx: Consultancy; Celgene: Consultancy.

APA, Harvard, Vancouver, ISO, and other styles

38

Menbaev, S. "COVID-19 PREVALENCE AMONG CANCER PATIENTS IN KAZAKHSTAN." Oncologia i radiologia Kazakhstana 66, no. 4 (December 30, 2022): 10–17. http://dx.doi.org/10.52532/2521-6414-2022-4-66-10-17.

Full text

Abstract:

Relevance: The new coronavirus infection, COVID-19, has been spreading rapidly around the world since 2019, affecting the healthcare systems of most countries. According to recent studies, malignant diseases increase the susceptibility to COVID-19 and are a risk factor for worse clinical outcomes in COVID-19 patients. COVID-19 also increases the risk of disease progression in patients with malignancies. The study aimed to study the prevalence of COVID-19 among cancer patients in Kazakhstan. Methods: The analysis included open-access articles published since 2019 and indexed in PubMed, Cochrane, Google Scholar, and e-Library by keywords “cancer,” “malignant neoplasms,” “COVID-19”, “cancer patients,” “mortality risk.” The official statistics data, medical information systems of the Republic of Kazakhstan (Electronic Register of Cancer Patients, Electronic Register of Inpatient Patients), and official periodicals on cancer incidence and mortality for 2020-2021 and COVID-19 incidence and mortality for 2020-2022 in Kazakhstan were studied. Results: In the Republic of Kazakhstan, in 2020-2021, the highest cancer incidence was registered in the North Kazakhstan (1.79-1.87%), Pavlodar (1.57-1.63%), Karaganda (1.54-1.53%) and Kostanay (1.53%) regions. The lowest rates were recorded in the Turkestan (0.42-0.41%), Kyzylorda (0.57-0.59%), and Mangistau (0.62%) regions, and the city of Shymkent (0.60%). The highest cancer mortality in Kazakhstan was registered in the Turkestan (11.1%), Kyzylorda (10.2%), and Zhambyl (10.02%) regions in 2020, and in they Atyrau (25.4%), Turkestan (10.68%), and West Kazakhstan (10.30%) regions in 2021. The mortality from COVID-19 among patients registered for cancer in 2020 was the highest in the city of Astana (1.06%), the Kyzylorda (0.46%) and Turkestan (0.33%) regions, and in 2021 – in the cities of Shymkent (1.05%) and Astana (1,00%), the Atyrau (0.93%) and West Kazakhstan (0.94%) regions. Conclusion: Thus, COVID-19 prevalence among cancer patients and their increased mortality during the pandemic, including the cases where the main cause of death was not an oncological process but the consequences of the viral infection, evidence the need to adjust the rules of statistical recording of cancer patients morbidity and mortality, the algorithms and protocols of diagnosis and treatment of cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

39

Menbaev, S. "COVID-19 PREVALENCE AMONG CANCER PATIENTS IN KAZAKHSTAN." Oncologia i radiologia Kazakhstana 66, no. 4 (December 30, 2022): 10–17. http://dx.doi.org/10.52532/2663-4864-2022-4-66-10-17.

Full text

Abstract:

ABSTRACT Relevance: The new coronavirus infection, COVID-19, has been spreading rapidly around the world since 2019, affecting the healthcare systems of most countries. According to recent studies, malignant diseases increase the susceptibility to COVID-19 and are a risk factor for worse clinical outcomes in COVID-19 patients. COVID-19 also increases the risk of disease progression in patients with malignancies. The study aimed to: study the prevalence of COVID-19 among cancer patients in Kazakhstan. Methods: The analysis included open-access articles published since 2019 and indexed in PubMed, Cochrane, Google Scholar, and e-Library by keywords “cancer,” “malignant neoplasms,” “COVID-19”, “cancer patients,” “mortality risk.” The official statistics data, medical information systems of the Republic of Kazakhstan (Electronic Register of Cancer Patients, Electronic Register of Inpatient Patients), and official periodicals on cancer incidence and mortality for 2020-2021 and COVID-19 incidence and mortality for 2020-2022 in Kazakhstan were studied. Results: In the Republic of Kazakhstan, in 2020-2021, the highest cancer incidence was registered in the North Kazakhstan (1.79-1.87%), Pavlodar (1.57-1.63%), Karaganda (1.54-1.53%) and Kostanay (1.53%) regions. The lowest rates were recorded in the Turkestan (0.42-0.41%), Kyzylorda (0.57-0.59%), and Mangistau (0.62%) regions, and the city of Shymkent (0.60%). The highest cancer mortality in Kazakhstan was registered in the Turkestan (11.1%), Kyzylorda (10.2%), and Zhambyl (10.02%) regions in 2020, and in they Atyrau (25.4%), Turkestan (10.68%), and West Kazakhstan (10.30%) regions in 2021. The mortality from COVID-19 among patients registered for cancer in 2020 was the highest in the city of Astana (1.06%), the Kyzylorda (0.46%) and Turkestan (0.33%) regions, and in 2021 – in the cities of Shymkent (1.05%) and Astana (1,00%), the Atyrau (0.93%) and West Kazakhstan (0.94%) regions. Conclusion: Thus, COVID-19 prevalence among cancer patients and their increased mortality during the pandemic, including the cases where the main cause of death was not an oncological process but the consequences of the viral infection, evidence the need to adjust the rules of statistical recording of cancer patients morbidity and mortality, the algorithms and protocols of diagnosis and treatment of cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

40

Dalsgaard, Sofie Bünemann, Else Toft Würtz, Johnni Hansen, Oluf Dimitri Røe, and Øyvind Omland. "Cancer Incidence and Risk of Multiple Cancers after Environmental Asbestos Exposure in Childhood—A Long-Term Register-Based Cohort Study." International Journal of Environmental Research and Public Health 19, no. 1 (December 27, 2021): 268. http://dx.doi.org/10.3390/ijerph19010268.

Full text

Abstract:

Objectives: To examine the asbestos-associated cancer incidence and the risk of multiple cancers in former school children exposed to environmental asbestos in childhood. Methods: A cohort of 12,111 former school children, born 1940–1970, was established using 7th grade school records from four schools located at a distance of 100–750 m in the prevailing wind direction from a large asbestos-cement plant that operated from 1928 to 1984 in Aalborg, Denmark. Using the unique Danish personal identification number, we linked information on employments, relatives’ employments, date of cancer diagnosis, and type of cancer and vital status to data on cohortees extracted from the Supplementary Pension Fund Register (employment history), the Danish Cancer Registry, and the Danish Civil Registration System. We calculated standardized incidence rates (SIRs) for asbestos-associated cancers, all cancers, and multiple cancers using rates for a gender and five-year frequency-matched reference cohort. Results: The overall incidence of cancer was modestly increased for the school cohort (SIR 1.07, 95% confidence interval (CI) 1.02–1.12) compared with the reference cohort. This excess was driven primarily by a significantly increased SIR for malignant mesothelioma (SIR 8.77, 95% CI 6.38–12.05). Former school children who had combined childhood environmental and subsequent occupational exposure to asbestos had a significantly increased risk of lung cancer. Within this group, those with additional household exposure by a relative had a significantly increased SIR for cancer of the pharynx (SIR 4.24, 95% CI 1.59–11.29). We found no significant difference in the number of subjects diagnosed with multiple cancers between the two cohorts. Conclusions: Our study confirms the strong association between environmental asbestos exposure and malignant mesothelioma and suggests that environmental asbestos exposure in childhood may increase the overall cancer risk later in life.

APA, Harvard, Vancouver, ISO, and other styles

41

Berinder, Katarina, Olof Akre, Fredrik Granath, and Anna-Lena Hulting. "Cancer risk in hyperprolactinemia patients: a population-based cohort study." European Journal of Endocrinology 165, no. 2 (August 2011): 209–15. http://dx.doi.org/10.1530/eje-11-0076.

Full text

Abstract:

ObjectiveExperimental evidence indicates that prolactin might play a role in tumorigenesis of several human cancers, but data on cancer risk in hyperprolactinemia patients are sparse. The aim of this study was to investigate cancer risk in hyperprolactinemia patients.DesignA population-based matched cohort study in Sweden.MethodsThe hyperprolactinemia cohort consisted of patients hospitalized for hyperprolactinemia from 1987 to 1995 identified in the National Patient Register (n=585) and a hospital cohort of prolactinoma patients at Karolinska University Hospital (n=384). For each patient, ten matched individuals were identified via the Register of Population. Cancer occurrence was ascertained via the Swedish Cancer Registry. Hazard ratios (HRs) were estimated by Cox proportional hazards regression.ResultsSeventy-three malignant tumors were identified in the hyperprolactinemia patients and 660 tumors in the comparison group (HR 1.31; 95% confidence interval (CI): 1.02–1.68), mainly attributed to an increased risk of upper gastrointestinal cancer in both males and females (HR 3.69; 95% CI: 1.70–8.03) and hematopoietic cancer in females (HR 3.51; 95% CI: 1.06–11.6). Twelve breast cancers occurred in the female patients, corresponding to an HR of 1.09 (95% CI: 0.60–1.99). Prostate cancer risk in hyperprolactinemia men was reduced (HR 0.40; 95% CI: 0.16–0.99).ConclusionsAn increased overall cancer risk was found in hyperprolactinemia patients, but no increased risk of breast cancer in women and a reduced risk of prostate cancer in men. These findings warrant further investigations and to be confirmed in larger studies but may indicate the importance of an active treatment strategy and follow-up of hyperprolactinemia patients.

APA, Harvard, Vancouver, ISO, and other styles

42

Hagel, Eva, Hans Garmo, Anna Bill-Axelson, Ola Bratt, Jan-Erik Johansson, Jan Adolfsson, Mats Lambe, and Pär Stattin. "PCBaSe Sweden: A register-based resource for prostate cancer research." Scandinavian Journal of Urology and Nephrology 43, no. 5 (January 2009): 342–49. http://dx.doi.org/10.3109/00365590903024577.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wiklund, K., and G. Eklund. "Reliability of Record Linkage in the Swedish Cancer-Environment Register." Acta Radiologica: Oncology 25, no. 1 (January 1986): 11–14. http://dx.doi.org/10.3109/02841868609136369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

MALKER, HANS S. R., JAN A. WEINER, and JOSEPH K. McLAUGHLIN. "Register Epidemiology Studies of Recent Cancer Trends in Selected Workers." Annals of the New York Academy of Sciences 609, no. 1 (November 1990): 322–32. http://dx.doi.org/10.1111/j.1749-6632.1990.tb32079.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Bratt, Ola, Linda Drevin, Karl-Göran Prütz, Stefan Carlsson, Lars Wennberg, and Pär Stattin. "Prostate cancer in kidney transplant recipients - a nationwide register study." BJU International 125, no. 5 (February 12, 2020): 679–85. http://dx.doi.org/10.1111/bju.15002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Grönberg, Henrik, Lena Damber, and Jan Erik Damber. "Familial prostate cancer in sweden: A nationwide register cohort study." Cancer 77, no. 1 (January 1, 1996): 138–43. http://dx.doi.org/10.1002/(sici)1097-0142(19960101)77:1<138::aid-cncr23>3.0.co;2-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Uusitalo, Elina, Matti Rantanen, Roope A. Kallionpää, Minna Pöyhönen, Jussi Leppävirta, Heli Ylä-Outinen, Vincent M. Riccardi, et al. "Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1." Journal of Clinical Oncology 34, no. 17 (June 10, 2016): 1978–86. http://dx.doi.org/10.1200/jco.2015.65.3576.

Full text

Abstract:

Purpose The current study was designed to determine the risk of cancer in patients with neurofibromatosis type 1 (NF1) by cancer type, age, and sex with unprecedented accuracy to be achieved by combining two total population–based registers. Patients and Methods A population-based series of patients with NF1 (N = 1,404; 19,076 person-years) was linked to incident cancers recorded in the Finnish Cancer Registry and deaths recorded in the national Population Register Centre between 1987 and 2012. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calculated for selected cancer types. Survival of the patients with cancer with and without NF1 was compared. Results In malignant peripheral nerve sheath tumors and CNS tumors, the cancers traditionally associated with NF1, we observed SIRs of 2,056 (95% CI, 1,561 to 2,658), and 37.5 (95% CI, 30.2 to 46.0), respectively, and SMRs of 2,301 (95% CI, 1,652 to 3,122) and 30.2 (95% CI, 19.1 to 45.2), respectively. We found an unequivocally increased risk for breast cancer. In particular, SIR was 11.1 (95% CI, 5.56 to 19.5) for breast cancer in women with NF1 age < 40 years; the overall SMR for breast cancer was 5.20 (95% CI, 2.38 to 9.88). Particularly high overall SIRs were observed in patients with NF1 age < 15 years: women, 87.6 (95% CI, 58.6 to 125); men, 45.6 (95% CI, 28.4 to 68.5). An estimated lifetime cancer risk for patients with NF1 was 59.6%. The 5-year survival of patients with cancer and NF1, excluding nervous tissue cancers, was worse than that of comparable patients with cancers without NF1 (54.0% v 67.5%; P = .01). Conclusion Our results emphasize the general cancer proclivity of patients with NF1. These findings should translate to clinical practices to determine clinical interventions and focused follow-up of patients with NF1.

APA, Harvard, Vancouver, ISO, and other styles

48

Oo, Yin Thet Nu, Thanda Linn, Khine Pwint Nwe, Win Pa Pa Naing, Ssu Wynn Mon, Hsu Theingi, Nan Cho Nwe Mon, et al. "Feasibility of Developing a Community-Based Cancer Registry in Kawa Township in Myanmar." JCO Global Oncology 6, Supplement_1 (July 2020): 32. http://dx.doi.org/10.1200/go.20.27000.

Full text

Abstract:

PURPOSE The objectives of this implementation research were to implement an innovative approach by basic health staff (BHS) using a cancer registry mobile application for continuous data reporting and to evaluate the process of establishing a community-based cancer registry. METHODS Eighty BHS in Kawa township, Bago region, were trained on the mobile application based on locally adapted CanReg5 software, common cancers and symptoms, and plans for implementation and monitoring. Required information of confirmed cancer cases was collected by the focal persons among local BHS using the application installed on their mobile devices and reported online to a database accessed by researchers. Two focus group discussions with BHS were conducted to identify challenges encountered during implementation and their suggested practical solutions. RESULTS A total of 74 confirmed cancer cases were registered during the 6-month implementation period. The most common cancers registered were breast cancer (20 cases), followed by GI cancers (18 cases) and lung cancers (9 cases). This finding was consistent with common cancers from regional hospital reports. Some data incompleteness was observed in topography, staging, and treatment information. In qualitative discussions, BHS reported technical difficulties in becoming familiar with morphologic codes, in saving registered cases in their phones, and in reading biopsy results and clinical notes. BHS approached family members mostly to obtain the hospital/laboratory records of patients with confirmed cases and some faced reluctance as family members did not want to inform the patients about their diagnosis. BHS could not register some cases when documents were not present, although they definitely knew the cases, including expired cases. The patient and/or caregiver expected financial or other support when they were registered. Once cancer is highly suspected or diagnosed, patients stop seeking proper care and turn to traditional healers. This is a result of the lack of knowledge about cancer. The cost of cancer health care is also a factor that influences whether treatment is sought. CONCLUSION A community-based cancer registry by BHS is feasible to a certain extent with some improvements. More community participation and proper referral to facilitate care are needed, as well as addressing technical difficulties.

APA, Harvard, Vancouver, ISO, and other styles

49

Lynge, Elsebeth, Anna-Belle Beau, My von Euler-Chelpin, George Napolitano, Sisse Njor, Anne Helene Olsen, Walter Schwartz, and Ilse Vejborg. "Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark." Breast Cancer Research and Treatment 184, no. 3 (August 30, 2020): 891–99. http://dx.doi.org/10.1007/s10549-020-05896-9.

Full text

Abstract:

Abstract Introduction Service breast cancer screening is difficult to evaluate because there is no unscreened control group. Due to a natural experiment, where 20% of women were offered screening in two regions up to 17 years before other women, Denmark is in a unique position. We utilized this opportunity to assess outcome of service screening. Materials and methods Screening was offered in Copenhagen from 1991 and Funen from 1993 to women aged 50–69 years. We used difference-in-differences methodology with a study group offered screening; a historical control group; a regional control group; and a regional–historical control group, comparing breast cancer mortality and incidence, including ductal carcinoma in situ, between study and historical control group adjusted for changes in other regions, and calculating ratios of rate ratios (RRR) with 95% confidence intervals (CI). Data came from Central Population Register; mammography screening databases; Cause of Death Register; and Danish Cancer Register. Results For breast cancer mortality, the study group accumulated 1,551,465 person-years and 911 deaths. Long-term breast cancer mortality in Copenhagen was 20% below expected in absence of screening; RRR 0.80 (95% CI 0.71–0.90), and in Funen 22% below; RRR 0.78 (95% CI 0.68–0.89). Combined, cumulative breast cancer incidence in women followed 8+ years post-screening was 2.3% above expected in absence of screening; RRR 1.023 (95% CI 0.97–1.08). Discussion Benefit-to-harm ratio of the two Danish screening programs was 2.6 saved breast cancer deaths per overdiagnosed case. Screening can affect only breast cancers diagnosed in screening age. Due to high breast cancer incidence after age 70, only one-third of breast cancer deaths after age 50 could potentially be affected by screening. Increasing upper age limit could be considered, but might affect benefit-to-harm ratio negatively.

APA, Harvard, Vancouver, ISO, and other styles

50

Harmenberg, Ulrika, Sven Lundstam, Thomas Wahlgren, Jan Kowalski, Maria Jakobsson, Rickard Sandin, Börje Ljungberg, and Per Sandström. "Treatment and overall survival (OS) in metastatic renal cell carcinoma (mRCC): A Swedish population-based study (2000–2008)." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 389. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.389.

Full text

Abstract:

389 Background: This retrospective register study assessed OS in all mRCC patients in Sweden diagnosed before (2000–2005) and after (2006–2008) the introduction of targeted therapies, plus factors and treatment options influencing OS. Methods: Three Swedish national health registers were used: the Swedish Cancer register (diagnosis and death), the National Patient Register (in-/out-patient data), and the Swedish Prescribed Drug Register. From 2000-2008, 3,243 patients were identified with mRCC; 602 were recorded as receiving 1st-line treatment. Cox proportional hazards regression analysis, including estimation of adjusted OS, was used in three models with the covariates: diagnosis period, age, gender, institution size, nephrectomy status, geographic region (all models); mRCC treatments, defined as any tyrosine kinase inhibitor (TKI; Model 1; n=417); sunitinib (SU), sorafenib (SO), and interferon-alfa (IFN-α) in the 1st-line setting (Model 2; n=602 [SU=244, SO=110, IFN-α=248]); and variations of these drugs as 1st- and 2nd-line treatment sequences (Model 3; n=602). Results: Amongst mRCC patients diagnosed from 2006–2008 compared with 2000–2005, median adjusted OS was 16.1 vs. 10.9 months, respectively (HR=0.76, 95% CI: 0.69, 0.83; P<0.001). In all three models, factors independently associated with significantly improved OS included female gender, large institution, and prior nephrectomy. Prescription of any TKI (Model 1: HR=0.82, 95% CI: 0.73, 0.93; P=0.002) and 1st-line SU treatment (Model 2: HR=0.79, 95% CI: 0.67, 0.94; P=0.007) were associated with significantly improved OS compared with other or no treatments. A similar significant improvement in OS was also confirmed for patients treated with SU only in Model 3; however, due to a low number of observations, the model had insufficient statistical power to be appropriate for all sequences. Conclusions: An improved OS for mRCC patients was demonstrated for the period 2006-2008 compared with 2000-2005. Although the observed survival advantage is multifactorial in origin, contribution of targeted therapies is highly probable. Of the drugs studied, given design limitations, only SU was associated with improved OS.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!